XML 69 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Disclosures (Tables)
12 Months Ended
Nov. 30, 2019
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis
The following is a summary of our financial assets and liabilities that are accounted for at fair value on a recurring basis, excluding Investments at fair value based on net asset value (“NAV”) of $570.3 million and $322.9 million at November 30, 2019 and 2018, respectively, by level within the fair value hierarchy (in thousands):
 
November 30, 2019
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and Cash Collateral Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,325,116

 
$
218,403

 
$
58,301

 
$

 
$
2,601,820

Corporate debt securities

 
2,472,213

 
7,490

 

 
2,479,703

Collateralized debt obligations and collateralized loan obligations

 
124,225

 
20,081

 

 
144,306

U.S. government and federal agency securities
2,101,624

 
158,618

 

 

 
2,260,242

Municipal securities

 
742,326

 

 

 
742,326

Sovereign obligations
1,330,026

 
1,405,827

 

 

 
2,735,853

Residential mortgage-backed securities

 
1,069,066

 
17,740

 

 
1,086,806

Commercial mortgage-backed securities

 
424,060

 
6,110

 

 
430,170

Other asset-backed securities

 
303,847

 
42,563

 

 
346,410

Loans and other receivables

 
2,395,211

 
64,240

 

 
2,459,451

Derivatives
2,809

 
1,812,659

 
14,889

 
(1,432,806
)
 
397,551

Investments at fair value

 
32,688

 
75,738

 

 
108,426

Total financial instruments owned, excluding Investments at fair value based on NAV
$
5,759,575

 
$
11,159,143

 
$
307,152

 
$
(1,432,806
)
 
$
15,793,064

Securities purchased under agreements to resell
$

 
$

 
$
25,000

 
$

 
$
25,000

Securities received as collateral
$
9,500

 
$

 
$

 
$

 
$
9,500

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,755,601

 
$
7,438

 
$
4,487

 
$

 
$
2,767,526

Corporate debt securities

 
1,471,142

 
340

 

 
1,471,482

U.S. government and federal agency securities
1,851,981

 

 

 

 
1,851,981

Sovereign obligations
1,363,475

 
941,065

 

 

 
2,304,540

Commercial mortgage-backed securities

 

 
35

 

 
35

Loans

 
1,600,228

 
9,463

 

 
1,609,691

Derivatives
871

 
2,066,064

 
92,057

 
(1,631,787
)
 
527,205

Total financial instruments sold, not yet purchased
$
5,971,928

 
$
6,085,937

 
$
106,382

 
$
(1,631,787
)
 
$
10,532,460

Short-term borrowings
$

 
$
20,981

 
$

 
$

 
$
20,981

Obligation to return securities received as collateral
$
9,500

 
$

 
$

 
$

 
$
9,500

Long-term debt
$

 
$
735,216

 
$
480,069

 
$

 
$
1,215,285

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
 
November 30, 2018
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and Cash Collateral Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,907,945

 
$
118,681

 
$
51,040

 
$

 
$
2,077,666

Corporate debt securities

 
2,683,180

 
9,484

 

 
2,692,664

Collateralized debt obligations and collateralized loan obligations

 
72,949

 
25,815

 

 
98,764

U.S. government and federal agency securities
1,789,614

 
56,592

 

 

 
1,846,206

Municipal securities

 
894,253

 

 

 
894,253

Sovereign obligations
1,769,556

 
1,043,409

 

 

 
2,812,965

Residential mortgage-backed securities

 
2,163,629

 
19,603

 

 
2,183,232

Commercial mortgage-backed securities

 
819,406

 
10,886

 

 
830,292

Other asset-backed securities

 
239,381

 
53,175

 

 
292,556

Loans and other receivables

 
2,056,593

 
46,985

 

 
2,103,578

Derivatives
12,186

 
2,524,988

 
5,922

 
(2,412,486
)
 
130,610

Investments at fair value

 

 
113,831

 

 
113,831

Total financial instruments owned, excluding Investments at fair value based on NAV
$
5,479,301

 
$
12,673,061

 
$
336,741

 
$
(2,412,486
)
 
$
16,076,617

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,685,071

 
$
1,444

 
$

 
$

 
$
1,686,515

Corporate debt securities

 
1,505,618

 
522

 

 
1,506,140

U.S. government and federal agency securities
1,384,295

 

 

 

 
1,384,295

Sovereign obligations
1,735,242

 
661,095

 

 

 
2,396,337

Loans

 
1,371,630

 
6,376

 

 
1,378,006

Derivatives
26,471

 
3,585,249

 
27,536

 
(2,511,605
)
 
1,127,651

Total financial instruments sold, not yet purchased
$
4,831,079

 
$
7,125,036

 
$
34,434

 
$
(2,511,605
)
 
$
9,478,944

Long-term debt
$

 
$
485,425

 
$
200,745

 
$

 
$
686,170

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
Investments Measured at Fair Value Based on Net Asset Value Per Share
The following tables present information about our investments in entities that have the characteristics of an investment company (in thousands):
 
November 30, 2019
 
Fair Value (1)
 
Unfunded Commitments
Equity Long/Short Hedge Funds (2)
$
291,593

 
$

Equity Funds (3)
27,952

 
12,108

Commodity Fund (4)
16,025

 

Multi-asset Funds (5)
234,583

 

Other Funds (6)
157

 

Total
$
570,310

 
$
12,108

 
November 30, 2018
 
Fair Value (1)
 
Unfunded Commitments
Equity Long/Short Hedge Funds (2)
$
15,338

 
$

Equity Funds (3)
40,070

 
20,996

Commodity Fund (4)
10,129

 

Multi-asset Funds (5)
256,972

 

Other Funds (6)
400

 

Total
$
322,909

 
$
20,996

(1)
Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements.
(2)
This category includes investments in hedge funds that invest, long and short, primarily in equity securities in domestic and international markets in both the public and private sectors. At November 30, 2019 and 2018, approximately 94% and 0%, respectively, of the fair value of investments in this category cannot be redeemed because these investments include restrictions that do not allow for redemption in the first 36 months after acquisition. At November 30, 2019 and 2018, approximately 6% and 97%, respectively, of the fair value of investments in this category are redeemable quarterly with 60 days prior written notice.
(3)
At November 30, 2019 and 2018, the investments in this category include investments in equity funds that invest in the equity of various U.S. and foreign private companies in the energy, technology, internet service and telecommunication service industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are primarily expected to be liquidated in approximately one to nine years.
(4)
This category includes investments in a hedge fund that invests, long and short, primarily in commodities. Investments in this category are redeemable quarterly with 60 days prior written notice.
(5)
This category includes investments in hedge funds that invest, long and short, primarily in multi-asset securities in domestic and international markets in both the public and private sectors. At November 30, 2019 and 2018, investments representing approximately 5% and 15%, respectively, of the fair value of investments in this category are redeemable with 30 days prior written notice.
(6)
This category includes investments in a fund that invests in loans secured by a first trust deed on property, domestic and international public high yield debt, private high yield investments, senior bank loans, public leveraged equities, distressed debt and private equity investments and there are no redemption provisions. This category also includes investments in a fund of funds that invests in various private equity funds that are managed by us and have no redemption provisions. Investments in the fund of funds are gradually being liquidated, however, the timing of when the proceeds will be received is uncertain.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the year ended November 30, 2018 (in thousands):
 
Balance at
November 
30, 2017
 
Total gains/
losses
(realized
and
unrealized)
(1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net
transfers
into/
(out of)
Level 3
 
Balance at
November
30, 2018
 
For instruments still held at November 30, 2018, changes in unrealized gains/(losses) included in:
 
 
 
 
 
 
 
 
 
Earnings (1)
 
Other
comprehensive
income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
22,009

 
$
24,023

 
$
31,669

 
$
(22,759
)
 
$
(3,977
)
 
$

 
$
75

 
$
51,040

 
$
22,774

 
$

Corporate debt securities
26,036

 
(439
)
 
10,352

 
(23,364
)
 
(1,679
)
 

 
(1,422
)
 
9,484

 
(2,606
)
 

CDOs and CLOs
30,004

 
(14,368
)
 
356,650

 
(353,330
)
 
(10,247
)
 

 
17,106

 
25,815

 
(7,605
)
 

RMBS
26,077

 
(6,970
)
 
3,118

 
(12,816
)
 
(513
)
 

 
10,707

 
19,603

 
521

 

CMBS
12,419

 
(2,186
)
 
1,436

 
(471
)
 
(16,624
)
 

 
16,312

 
10,886

 
(4,000
)
 

Other ABS
61,129

 
(9,934
)
 
706,846

 
(677,220
)
 
(27,641
)
 

 
(5
)
 
53,175

 
(5,283
)
 


Loans and other receivables
47,304

 
(5,137
)
 
149,228

 
(130,832
)
 
(15,311
)
 

 
1,733

 
46,985

 
(8,457
)
 

Investments at fair value
93,454

 
2,353

 
34,648

 
(17,570
)
 

 

 
946

 
113,831

 
1,759

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
48

 
$

 
$

 
$

 
$

 
$

 
$
(48
)
 
$

 
$

 
$

Corporate debt securities
522

 

 

 

 

 

 

 
522

 

 

CMBS
105

 
(105
)
 

 

 

 

 

 

 

 

Loans
3,486

 
84

 
(4,626
)
 
7,432

 

 

 

 
6,376

 
(28
)
 

Net derivatives (2)
6,746

 
(3,237
)
 
(17
)
 
14,920

 
(1,335
)
 

 
4,537

 
21,614

 
(646
)
 

Long-term debt

 
(30,347
)
 

 

 

 
84,860

 
146,232

 
200,745

 
10,951

 
19,396

(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the year ended November 30, 2019 (in thousands):
 
Balance at November 30, 2018

 
Total gains/ losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of)
Level 3
 
Balance at November 30, 2019
 
For instruments still held at November 30, 2019, changes in unrealized gains/(losses) included in:
 
 
 
 
 
 
 
 
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
51,040

 
$
(10,380
)
 
$
69,065

 
$
(28,159
)
 
$
(18,208
)
 
$

 
$
(5,057
)
 
$
58,301

 
$
(12,821
)
 
$

Corporate debt securities
9,484

 
(4,860
)
 
8,900

 
(13,854
)
 
(379
)
 

 
8,199

 
7,490

 
(6,176
)
 

CDOs and CLOs
25,815

 
(2,342
)
 
49,658

 
(38,147
)
 
(9,083
)
 

 
(5,820
)
 
20,081

 
(974
)
 

RMBS
19,603

 
(1,669
)
 
1,954

 
(2,472
)
 
(152
)
 

 
476

 
17,740

 
(530
)
 

CMBS
10,886

 
(2,888
)
 
206

 
(2,346
)
 
(5,317
)
 

 
5,569

 
6,110

 
(2,366
)
 

Other ABS
53,175

 
433

 
104,097

 
(73,335
)
 
(51,374
)
 

 
9,567

 
42,563

 
(98
)
 

Loans and other receivables
46,985

 
(5,505
)
 
57,403

 
(48,350
)
 
(5,068
)
 

 
18,775

 
64,240

 
(3,319
)
 

Investments at fair value
113,831

 
113

 
240

 
(38,446
)
 

 

 

 
75,738

 
2,964

 

Securities purchased under agreements to resell

 

 

 

 

 
25,000

 

 
25,000

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$

 
$
(2,649
)
 
$
(4,322
)
 
$
11,458

 
$

 
$

 
$

 
$
4,487

 
$
1,928

 
$

Corporate debt securities
522

 
(381
)
 
(457
)
 

 
(524
)
 

 
1,180

 
340

 
383

 

CMBS

 
35

 

 

 

 

 

 
35

 
35

 

Loans
6,376

 
(1,382
)
 
(2,573
)
 
6,494

 

 

 
548

 
9,463

 
1,382

 

Net derivatives (2)
21,614

 
(21,452
)
 
(4,323
)
 
36,144

 
2,227

 

 
42,958

 
77,168

 
12,098

 

Long-term debt
200,745

 
(18,662
)
 

 

 
(11,250
)
 
348,275

 
(39,039
)
 
480,069

 
29,656

 
(10,993
)
(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the year ended November 30, 2017 (in thousands):
 
Balance at November 30, 2016
 
Total gains/ losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/ (out of) Level 3
 
Balance at November 30, 2017
 
Change in unrealized gain/ (losses) relating to instruments still held at November 30, 2017 (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
21,739

 
$
3,262

 
$
896

 
$
(1,623
)
 
$
52

 
$

 
$
(2,317
)
 
$
22,009

 
$
2,515

Corporate debt securities
25,005

 
(3,723
)
 
36,850

 
(34,077
)
 
(1,968
)
 

 
3,949

 
26,036

 
(3,768
)
CDOs and CLOs
54,354

 
(19,858
)
 
112,239

 
(110,907
)
 
(367
)
 

 
(5,457
)
 
30,004

 
(2,262
)
Municipal securities
27,257

 
(1,547
)
 

 
(25,710
)
 

 

 

 

 

RMBS
38,772

 
(10,817
)
 
6,805

 
(26,193
)
 
(115
)
 

 
17,625

 
26,077

 
(7,201
)
CMBS
20,580

 
(5,346
)
 
3,275

 
(5,263
)
 
(1,018
)
 

 
191

 
12,419

 
(6,976
)
Other ABS
40,911

 
(17,705
)
 
77,508

 
(8,613
)
 
(25,799
)
 

 
(5,173
)
 
61,129

 
(12,562
)
Loans and other receivables
81,872

 
24,794

 
63,768

 
(53,095
)
 
(34,622
)
 

 
(35,413
)
 
47,304

 
17,451

Investments, at fair value
96,369

 
6,361

 
1,981

 
(10,157
)
 
(1,100
)
 

 

 
93,454

 
8,385

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
313

 
$
60

 
$
(373
)
 
$
48

 
$

 
$

 
$

 
$
48

 
$

Corporate debt securities
523

 
(1
)
 

 

 

 

 

 
522

 
1

CMBS

 
105

 

 

 

 

 

 
105

 
(105
)
Loans
378

 
196

 
(385
)
 
2,485

 

 

 
812

 
3,486

 
(2,639
)
Net derivatives (2)
3,441

 
(1,638
)
 

 

 
5,558

 
456

 
(1,071
)
 
6,746

 
(17,740
)
Other secured financings
418

 
(418
)
 

 

 

 

 

 

 

(1)
Realized and unrealized gains/losses are reported in Principal transactions revenues in our Consolidated Statements of Earnings.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the year ended November 30, 2018 (in thousands):
 
Balance at
November 
30, 2017
 
Total gains/
losses
(realized
and
unrealized)
(1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net
transfers
into/
(out of)
Level 3
 
Balance at
November
30, 2018
 
For instruments still held at November 30, 2018, changes in unrealized gains/(losses) included in:
 
 
 
 
 
 
 
 
 
Earnings (1)
 
Other
comprehensive
income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
22,009

 
$
24,023

 
$
31,669

 
$
(22,759
)
 
$
(3,977
)
 
$

 
$
75

 
$
51,040

 
$
22,774

 
$

Corporate debt securities
26,036

 
(439
)
 
10,352

 
(23,364
)
 
(1,679
)
 

 
(1,422
)
 
9,484

 
(2,606
)
 

CDOs and CLOs
30,004

 
(14,368
)
 
356,650

 
(353,330
)
 
(10,247
)
 

 
17,106

 
25,815

 
(7,605
)
 

RMBS
26,077

 
(6,970
)
 
3,118

 
(12,816
)
 
(513
)
 

 
10,707

 
19,603

 
521

 

CMBS
12,419

 
(2,186
)
 
1,436

 
(471
)
 
(16,624
)
 

 
16,312

 
10,886

 
(4,000
)
 

Other ABS
61,129

 
(9,934
)
 
706,846

 
(677,220
)
 
(27,641
)
 

 
(5
)
 
53,175

 
(5,283
)
 


Loans and other receivables
47,304

 
(5,137
)
 
149,228

 
(130,832
)
 
(15,311
)
 

 
1,733

 
46,985

 
(8,457
)
 

Investments at fair value
93,454

 
2,353

 
34,648

 
(17,570
)
 

 

 
946

 
113,831

 
1,759

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
48

 
$

 
$

 
$

 
$

 
$

 
$
(48
)
 
$

 
$

 
$

Corporate debt securities
522

 

 

 

 

 

 

 
522

 

 

CMBS
105

 
(105
)
 

 

 

 

 

 

 

 

Loans
3,486

 
84

 
(4,626
)
 
7,432

 

 

 

 
6,376

 
(28
)
 

Net derivatives (2)
6,746

 
(3,237
)
 
(17
)
 
14,920

 
(1,335
)
 

 
4,537

 
21,614

 
(646
)
 

Long-term debt

 
(30,347
)
 

 

 

 
84,860

 
146,232

 
200,745

 
10,951

 
19,396

(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the year ended November 30, 2019 (in thousands):
 
Balance at November 30, 2018

 
Total gains/ losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of)
Level 3
 
Balance at November 30, 2019
 
For instruments still held at November 30, 2019, changes in unrealized gains/(losses) included in:
 
 
 
 
 
 
 
 
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
51,040

 
$
(10,380
)
 
$
69,065

 
$
(28,159
)
 
$
(18,208
)
 
$

 
$
(5,057
)
 
$
58,301

 
$
(12,821
)
 
$

Corporate debt securities
9,484

 
(4,860
)
 
8,900

 
(13,854
)
 
(379
)
 

 
8,199

 
7,490

 
(6,176
)
 

CDOs and CLOs
25,815

 
(2,342
)
 
49,658

 
(38,147
)
 
(9,083
)
 

 
(5,820
)
 
20,081

 
(974
)
 

RMBS
19,603

 
(1,669
)
 
1,954

 
(2,472
)
 
(152
)
 

 
476

 
17,740

 
(530
)
 

CMBS
10,886

 
(2,888
)
 
206

 
(2,346
)
 
(5,317
)
 

 
5,569

 
6,110

 
(2,366
)
 

Other ABS
53,175

 
433

 
104,097

 
(73,335
)
 
(51,374
)
 

 
9,567

 
42,563

 
(98
)
 

Loans and other receivables
46,985

 
(5,505
)
 
57,403

 
(48,350
)
 
(5,068
)
 

 
18,775

 
64,240

 
(3,319
)
 

Investments at fair value
113,831

 
113

 
240

 
(38,446
)
 

 

 

 
75,738

 
2,964

 

Securities purchased under agreements to resell

 

 

 

 

 
25,000

 

 
25,000

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$

 
$
(2,649
)
 
$
(4,322
)
 
$
11,458

 
$

 
$

 
$

 
$
4,487

 
$
1,928

 
$

Corporate debt securities
522

 
(381
)
 
(457
)
 

 
(524
)
 

 
1,180

 
340

 
383

 

CMBS

 
35

 

 

 

 

 

 
35

 
35

 

Loans
6,376

 
(1,382
)
 
(2,573
)
 
6,494

 

 

 
548

 
9,463

 
1,382

 

Net derivatives (2)
21,614

 
(21,452
)
 
(4,323
)
 
36,144

 
2,227

 

 
42,958

 
77,168

 
12,098

 

Long-term debt
200,745

 
(18,662
)
 

 

 
(11,250
)
 
348,275

 
(39,039
)
 
480,069

 
29,656

 
(10,993
)
(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the year ended November 30, 2017 (in thousands):
 
Balance at November 30, 2016
 
Total gains/ losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/ (out of) Level 3
 
Balance at November 30, 2017
 
Change in unrealized gain/ (losses) relating to instruments still held at November 30, 2017 (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
21,739

 
$
3,262

 
$
896

 
$
(1,623
)
 
$
52

 
$

 
$
(2,317
)
 
$
22,009

 
$
2,515

Corporate debt securities
25,005

 
(3,723
)
 
36,850

 
(34,077
)
 
(1,968
)
 

 
3,949

 
26,036

 
(3,768
)
CDOs and CLOs
54,354

 
(19,858
)
 
112,239

 
(110,907
)
 
(367
)
 

 
(5,457
)
 
30,004

 
(2,262
)
Municipal securities
27,257

 
(1,547
)
 

 
(25,710
)
 

 

 

 

 

RMBS
38,772

 
(10,817
)
 
6,805

 
(26,193
)
 
(115
)
 

 
17,625

 
26,077

 
(7,201
)
CMBS
20,580

 
(5,346
)
 
3,275

 
(5,263
)
 
(1,018
)
 

 
191

 
12,419

 
(6,976
)
Other ABS
40,911

 
(17,705
)
 
77,508

 
(8,613
)
 
(25,799
)
 

 
(5,173
)
 
61,129

 
(12,562
)
Loans and other receivables
81,872

 
24,794

 
63,768

 
(53,095
)
 
(34,622
)
 

 
(35,413
)
 
47,304

 
17,451

Investments, at fair value
96,369

 
6,361

 
1,981

 
(10,157
)
 
(1,100
)
 

 

 
93,454

 
8,385

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
313

 
$
60

 
$
(373
)
 
$
48

 
$

 
$

 
$

 
$
48

 
$

Corporate debt securities
523

 
(1
)
 

 

 

 

 

 
522

 
1

CMBS

 
105

 

 

 

 

 

 
105

 
(105
)
Loans
378

 
196

 
(385
)
 
2,485

 

 

 
812

 
3,486

 
(2,639
)
Net derivatives (2)
3,441

 
(1,638
)
 

 

 
5,558

 
456

 
(1,071
)
 
6,746

 
(17,740
)
Other secured financings
418

 
(418
)
 

 

 

 

 

 

 

(1)
Realized and unrealized gains/losses are reported in Principal transactions revenues in our Consolidated Statements of Earnings.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
Quantitative Information about Significant Unobservable Inputs Used in Level 3 Fair Value Measurements
The tables below present information on the valuation techniques, significant unobservable inputs and their ranges for our financial assets and liabilities, subject to threshold levels related to the market value of the positions held, measured at fair value on a recurring basis with a significant Level 3 balance. The range of unobservable inputs could differ significantly across different firms given the range of products across different firms in the financial services sector. The inputs are not representative of the inputs that could have been used in the valuation of any one financial instrument (i.e., the input used for valuing one financial instrument within a particular class of financial instruments may not be appropriate for valuing other financial instruments within that given class). Additionally, the ranges of inputs presented below should not be construed to represent uncertainty regarding the fair values of our financial instruments; rather, the range of inputs is reflective of the differences in the underlying characteristics of the financial instruments in each category.
For certain categories, we have provided a weighted average of the inputs allocated based on the fair values of the financial instruments comprising the category. We do not believe that the range or weighted average of the inputs is indicative of the reasonableness of uncertainty of our Level 3 fair values. The range and weighted average are driven by the individual financial instruments within each category and their relative distribution in the population. The disclosed inputs when compared with the inputs as disclosed in other periods should not be expected to necessarily be indicative of changes in our estimates of unobservable inputs for a particular financial instrument as the population of financial instruments comprising the category will vary from period to period based on purchases and sales of financial instruments during the period as well as transfers into and out of Level 3 each period.
November 30, 2019
Financial Instruments Owned
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
29,017

 
 
 
 
 
 
 
 
 
 
Non-exchange-traded securities
 
Market approach
 
Price
 
$1
-
$140
 
$
55

 
 
 
 
 
 
Underlying stock price
 
$3
-
$5
 
$
4

Corporate debt securities
 
$
7,490

 
Scenario analysis
 
Estimated recovery percentage
 
23
%
-
85%
 
46
%
 
 
 
 
 
 
Volatility
 
44%
 

 
 
 
 
 
 
Credit spread
 
750
 

 
 
 
 
 
 
Underlying stock price
 
£0.4
 

CDOs and CLOs
 
$
20,081

 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
1
%
-
2%
 
2
%
 
 
 
 
 
 
Loss severity
 
25
%
-
37%
 
29
%
 
 
 
 
 
 
Discount rate/yield
 
12
%
-
21%
 
15
%
RMBS
 
$
17,740

 
Discounted cash flows
 
Cumulative loss rate
 
2%
 

 
 
 
 
 
 
Duration (years)
 
6.3
 

 
 
 
 
 
 
Discount rate/yield
 
3%
 

CMBS
 
$
6,110

 
Discounted cash flows
 
Cumulative loss rate
 
7.3%
 

 
 
 
 
 
 
Duration (years)
 
0.2
 

 
 
 
 
 
 
Discount rate/yield
 
85%
 

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
44%
 

Other ABS
 
$
42,563

 
Discounted cash flows
 
Cumulative loss rate
 
7
%
-
31%
 
16
%
 
 
 
 
 
 
Duration (years)
 
0.5

-
3.0
 
1.5

 
 
 
 
 
 
Discount rate/yield
 
7
%
-
15%
 
11
%
Loans and other receivables
 
$
62,734

 
Market approach
 
Price
 
$36
-
$100
 
$
90

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
87
%
-
104%
 
99
%
Derivatives
 
$
13,826

 
 
 
 
 
 
 
 
 
 
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
16
 
6

Unfunded commitments
 
 
 
 
 
Price
 
$88
 

Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
45%
 

Investments at fair value
 
$
75,736

 
 
 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$8
-
$250
 
$
125

Securities purchased under agreements to resell
 
$
25,000

 
Market approach
 
Spread to 6 month LIBOR
 
500
 

 
 
 
 
 
 
Duration (years)
 
1.5
 

Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
 
$
4,487

 
Market approach
 
Transaction level
 
$1
 

Loans
 
$
9,463

 
Market approach
 
Price
 
$50
-
$100
 
$
88

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
1%
 

Derivatives
 
$
92,057

 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
21
%
-
61%
 
43
%
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
22
 
13

Cross currency swaps
 
 
 
 
 
Basis points upfront
 
2
 

Unfunded commitments
 
 
 
 
 
Price
 
$88
 

Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$
480,069

 
Market approach
 
Price
 
$84
-
$108
 
$
96

 
 
 
 
 
 
Price
 
€74
-
€103
 
91

November 30, 2018
Financial Instruments Owned:
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
43,664

 
 
 
 
 
 
 
 
 
 
Non-exchange-traded securities
 
Market approach
 
Price
 
$1
-
$75
 
$
12

 
 
 
 
 
 
Transaction level
 
$47
 

Corporate debt securities
 
$
9,484

 
Market approach
 
Estimated recovery percentage
 
46%
 

 
 
 
 
 
 
Transaction level
 
$80
 

CDOs and CLOs
 
$
25,815

 
Discounted cash flows
 
Constant prepayment rate
 
10
%
 -
20%
 
18
%
 
 
 
 
 
 
Constant default rate
 
1
%
 -
2%
 
2
%
 
 

 
 
 
Loss severity
 
25
%
 -
30%
 
26
%
 
 
 
 
 
 
Discount rate/yield
 
11
%
 -
16%
 
14
%
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
2%
 

RMBS
 
$
19,603

 
Discounted cash flows
 
Cumulative loss rate
 
4%
 

 
 

 
 
 
Duration (years)
 
13
 

 
 
 
 
 
 
Loss severity
 
0%
 

 
 
 
 
 
 
Discount rate/yield
 
3%
 

 
 
 
 
Market approach
 
Price
 
$100
 

CMBS
 
$
9,444

 
Discounted cash flows
 
Cumulative loss rate
 
8
%
 -
85%
 
45
%
 
 
 
 
 
 
Duration (years)
 
1

-
3
 
1

 
 
 
 
 
 
Loss severity
 
64%
 

 
 
 
 
 
 
Discount rate/yield
 
2
%
 -
15%
 
6
%
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
26%
 

 
 
 
 
 
 
Price
 
$49
 

Other ABS
 
$
53,175

 
Discounted cash flows
 
Cumulative loss rate
 
12
%
 -
30%
 
22
%
 
 
 
 
 
 
Duration (years)
 
1

-
2
 
1

 
 

 
 
 
Discount rate/yield
 
6
%
 -
12%
 
8
%
 
 
 
 
Market approach
 
Price
 
$100
 

Loans and other receivables
 
$
46,078

 
Market approach
 
Price
 
$50
-
$100
 
$
96

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
13
%
 -
117%
 
105
%
Derivatives
 
$
4,602

 
 
 
 
 
 
 
 
 
 
Total return swaps
 
 
 
Market approach
 
Price
 
$97
 

Investments at fair value
 
$
113,831

 
 
 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$3
-
$250
 
$
108

 
 
 
 
 
 
Transaction level
 
$169
 

 
 
 
 
Scenario analysis
 
Discount rate/yield
 
20%
 

 
 
 
 
 
 
Revenue growth
 
0%
 

Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
 
 
Loans
 
$
6,376

 
Market approach
 
Price
 
$50
-
$101
 
$
74

Derivatives
 
$
27,536

 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Option model/default rate
 
Default probability
 
0%
 

 
 
 
 
Volatility benchmarking
 
Volatility
 
39
%
 -
62%
 
50
%
Interest rate swaps
 
 
 
Market approach
 
Price
 
$20
 

Total return swaps
 
 
 
 
 
Price
 
$97
 

Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$
200,745

 
Market approach
 
Price
 
$78
-
$94
 
$
86

 
 
 
 
 
 
Price
 
€68
-
€110
 
96


Summary of Gains (Losses) Due to Changes in Instrument Specific Credit Risk and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables
The following is a summary of gains (losses) due to changes in instrument specific credit risk on loans, other receivables and debt instruments and gains (losses) due to other changes in fair value on Long-term debt and Short-term borrowings measured at fair value under the fair value option (in thousands):
 
Year Ended November 30,
 
2019
 
2018
 
2017
Financial instruments owned:
 
 
 
 
 
Loans and other receivables
$
(2,072
)
 
$
(3,856
)
 
$
22,088

Financial instruments sold, not yet purchased:
 
 
 
 
 
Loans
$
656

 
$
(46
)
 
$

Loan commitments
(1,089
)
 
(739
)
 
230

Long-term debt:
 
 
 
 
 
Changes in instrument specific credit risk (1)
$
(20,332
)
 
$
38,064

 
$
(34,609
)
Other changes in fair value (2)
(25,144
)
 
48,748

 
47,291

Short-term borrowings:
 
 
 
 
 
Changes in instrument specific credit risk (1)
$
114

 
$

 
$

Other changes in fair value (2)
(863
)
 

 
(681
)
(1)
Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Other changes in fair value are included in Principal transactions revenues in our Consolidated Statements of Earnings.
The following is a summary of the amount by which contractual principal exceeds fair value for loans and other receivables, long term debt and short-term borrowings measured at fair value under the fair value option (in thousands):
 
November 30,
 
2019
 
2018
Financial instruments owned:
 
 
 
Loans and other receivables (1)
$
1,546,516

 
$
961,554

Loans and other receivables on nonaccrual status and/or 90 days or
    greater past due (1) (2)
197,215

 
158,392

Long-term debt and short-term borrowings
74,408

 
114,669

(1)
Interest income is recognized separately from other changes in fair value and is included in Interest revenues in our Consolidated Statements of Earnings.
(2)
Amounts include loans and other receivables 90 days or greater past due by which contractual principal exceeds fair value of $22.2 million and $20.5 million at November 30, 2019 and 2018, respectively.
Assets and Liabilities Measured at Fair Value on a Non-recurring Basis The following table presents those assets measured at fair value on a non-recurring basis for which we recognized a non-recurring fair value adjustment during the years ended November 30, 2019, 2018 and 2017 (in thousands):
 
Carrying Value at November 30, 2019
 
Level 2
 
Level 3
 
Impairment Losses for the Year Ended November 30, 2019
Exchange ownership interests and registrations (1)
$
2,443

 
$
2,443

 
$

 
$
291

 
Carrying Value at November 30, 2018
 
Level 2
 
Level 3
 
Impairment Losses for the Year Ended November 30, 2018
Exchange ownership interests and registrations (1)
$
2,663

 
$
2,663

 
$

 
$
9

 
Carrying Value at November 30, 2017
 
Level 2
 
Level 3
 
Impairment Losses for the Year Ended November 30, 2017
Exchange ownership interests and registrations (1)
$
2,672

 
$
2,672

 
$

 
$
613

(1)
Impairment losses for exchange memberships, which represent ownership interests in market exchanges on which trading business is conducted, and registrations, were recognized in Other expenses. The fair value of these exchange memberships is based on observed quoted sales prices for each individual membership. (See Note 10, Goodwill and Intangible Assets.) The intangible assets are recognized for the years ended November 30, 2019, 2018 and 2017, primarily in the Fixed income reporting unit.